ARTICLE BY BIO X CELLTranslational Continuity: Why Drug Programs Fail EarlyIn a recent blog post titled "Translational Continuity: Why Drug Programs Fail Early," Bio X Cell  introduced insights into why over 90% of drug candidates fail during clinical trials. A...

ARTICLE BY BIO X CELLFactors That Influence Antibody Performance In VivoBio X Cell has recently published an insightful guide titled “Factors That Influence Antibody Performance In Vivo,” addressing a critical hurdle in preclinical and translational research. As...

ARTICLE BY BIO X CELLEmerging Therapeutic Strategies in Cancer ResearchBio X Cell has recently published a comprehensive piece titled “Emerging Therapeutic Strategies in Cancer Research.” Oncology is transitioning into a new era defined by precision, biological...

ARTICLE BY BIO X CELLBio X Cell Introduces First Commercially Available Anti-Mouse Trispecific Antibody for Preclinical ResearchBio X Cell has announced the launch of the first commercially available, ready-to-use anti-mouse PD-L1 × TIGIT × LAG3 trispecific antibody...

ARTICLE BY BIO X CELLThe Reproducibility Crisis Is a Reagent CrisisFor more than a decade, concerns regarding scientific reproducibility have echoed across funding agencies, academic journals, and research laboratories worldwide. While investigators typically...

ARTICLE BY BIO X CELLHow Fc Engineering Improves Mechanistic Clarity in In Vivo StudiesBio X Cell has recently published a highly informative piece titled “How Fc Engineering Improves Mechanistic Clarity in In Vivo Studies.” As researchers transition their work from...